Login / Signup

Emerging drugs for the treatment of cutaneous T-cell lymphoma.

Melissa ChengJasmine ZainSteven T RosenChristiane Querfeld
Published in: Expert opinion on emerging drugs (2022)
Mogamulizumab and brentuximab vedotin have reached the market and are approved for the treatment of CTCL, providing valuable options. Additionally, therapies utilizing immune checkpoint inhibitors, miRNA inhibitors, and peptide inhibitors show promising results in clinical trials. Durvalumab, pembrolizumab, TTI-621, BNZ-1, and MRG-106 are several of the emerging treatments still in trials. Further combinatorial studies are needed as none of the treatments have demonstrated long-term remissions.
Keyphrases
  • clinical trial
  • hodgkin lymphoma
  • combination therapy
  • open label
  • advanced non small cell lung cancer
  • epidermal growth factor receptor